CUE — Cue Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645460 ·
Last close
$26.84
Market Cap
$112.74M
52W High
$45.50
52W Low
$18.20
ADV30
153,853
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 5,686,000 | — | -5,363,000 | -5,178,000 | 30,877,000 | 16,379,000 | 9,269,000 |
| Dec 2025 | 21,942,000 | — | 1,958,000 | 1,585,000 | 42,212,000 | 27,136,000 | 15,780,000 |
| Sep 2025 | 2,149,000 | — | -7,544,000 | -7,448,000 | 31,644,000 | 11,701,000 | 18,398,000 |
| Jun 2025 | 2,954,000 | — | -8,635,000 | -8,482,000 | 40,707,000 | 27,492,000 | 22,548,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,457,000
Investing CF
$104,000
Financing CF
$27,597,000
CapEx
$-300,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.58
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-373,644,000
Inventory
—
Receivables
$7,250,000
ST Investments
$6,971,000
EBIT TTM
$-18,848,000
Pretax Income TTM
$-19,023,000
Interest Exp TTM
$175,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,731,000
EBITDA
$-18,162,000
Free Cash Flow
$-14,895,250
Enterprise Value
$94,585,616
Total Cash
$17,441,000
Total Debt
$3,440,000
Shares Out
4,200,343
Trailing EPS
$-4.53
Book Value
$6.64
ROE
-138.5%
ROA
-46.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 27,466,000 | -26,521,000 | -26,602,000 | 42,212,000 | 15,780,000 | — | -21,687,000 |
| Dec 2024 | 9,287,000 | -41,593,000 | -40,674,000 | 32,191,000 | 14,692,000 | — | -36,329,000 |
| Dec 2023 | 5,490,000 | -51,992,000 | -50,733,000 | 61,530,000 | 24,445,000 | — | -39,961,000 |
| Dec 2022 | 1,245,000 | -53,502,000 | -53,010,000 | 91,283,000 | 25,601,000 | — | -41,806,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc. | $109.36M | $2.31 | — |
| ANIX | Anixa Biosciences Inc | $116.36M | $3.42 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $117.88M | $42.83 | — |
| BGM | BGM Group Ltd. | $107.34M | $0.28 | — |
| PEPG | PepGen Inc. | $121.74M | $1.76 | — |
News headlines (Yahoo Finance, 1h cache)
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
2026-07-24 05:56 · Yahoo
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
2026-07-13 17:00 · Yahoo
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
2026-07-13 12:30 · Yahoo
Cue Biopharma Announces $50.0 Million Private Placement
2026-07-10 01:40 · Yahoo
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
2026-06-02 20:05 · Yahoo
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-21 20:05 · Yahoo
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-05-14 20:07 · Yahoo
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 23:07 · Yahoo
Cue Biopharma Announces $30 Million Private Placement
2026-04-30 20:25 · Yahoo
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
2026-04-30 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.